YU47543B - Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita - Google Patents

Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita

Info

Publication number
YU47543B
YU47543B YU134287A YU134287A YU47543B YU 47543 B YU47543 B YU 47543B YU 134287 A YU134287 A YU 134287A YU 134287 A YU134287 A YU 134287A YU 47543 B YU47543 B YU 47543B
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical preparation
granullocyte
stimulation
procedure
obtaining pharmaceutical
Prior art date
Application number
YU134287A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU134287A (en
Inventor
M. Machida
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of YU134287A publication Critical patent/YU134287A/xx
Publication of YU47543B publication Critical patent/YU47543B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
YU134287A 1986-07-18 1987-07-17 Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita YU47543B (sh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948786 1986-07-18
JP16948886 1986-07-18
JP16948686 1986-07-18
JP16948986 1986-07-18

Publications (2)

Publication Number Publication Date
YU134287A YU134287A (en) 1989-06-30
YU47543B true YU47543B (sh) 1995-10-03

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
YU134287A YU47543B (sh) 1986-07-18 1987-07-17 Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita

Country Status (24)

Country Link
KR (1) KR930004597B1 (da)
CN (1) CN1033738C (da)
AT (1) AT402259B (da)
AU (1) AU611856B2 (da)
BE (1) BE1000253A3 (da)
CA (1) CA1297007C (da)
CH (1) CH671157A5 (da)
DE (1) DE3723781C2 (da)
DK (1) DK171308B1 (da)
ES (1) ES2010226A6 (da)
FR (1) FR2601591B1 (da)
GB (1) GB2193631B (da)
GR (1) GR871067B (da)
HK (1) HK64893A (da)
HU (1) HU198627B (da)
IE (1) IE60290B1 (da)
IL (1) IL83220A (da)
IT (1) IT1218927B (da)
NL (1) NL192917C (da)
NO (1) NO171828C (da)
PT (1) PT85343B (da)
SE (1) SE503312C2 (da)
SG (1) SG64393G (da)
YU (1) YU47543B (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693907B1 (fr) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'administration de solutions de facteur de stimulation des colonies granulocytaires.
EP0582932A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
EP1232753B1 (en) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
TR200401573T4 (tr) * 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilize edilmiş granülosit koloni uyarıcı faktör
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
NZ524482A (en) * 2000-09-01 2005-11-25 Chugai Pharmaceutical Co Ltd Solution formulations having long-term stability
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2517310C (en) 2003-02-28 2015-11-24 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations comprising a poloxamer
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
WO2008075370A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US9867777B2 (en) 2010-01-19 2018-01-16 Hanmi Science Co., Ltd. Liquid formulations for long-acting G-CSF conjugate
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10993985B2 (en) 2016-02-23 2021-05-04 BioLmeRx Ltd. Methods of treating acute myeloid leukemia
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
AU523077B2 (en) * 1978-03-20 1982-07-08 Green Cross Corporation, The Hgi glycoprotein
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (ja) * 1984-04-26 1985-11-13 Suntory Ltd 安定化された生理活性物質製剤
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
DE3686794T2 (de) * 1985-02-05 1993-03-04 Cetus Oncology Corp Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
GR871067B (en) 1987-11-19
BE1000253A3 (fr) 1988-09-27
SE503312C2 (sv) 1996-05-13
ATA177587A (de) 1996-08-15
NO872966D0 (no) 1987-07-16
DK368387A (da) 1988-01-19
SE8702907L (sv) 1988-01-19
YU134287A (en) 1989-06-30
KR880001297A (ko) 1988-04-22
FR2601591A1 (fr) 1988-01-22
IL83220A (en) 1993-01-31
ES2010226A6 (es) 1989-11-01
HK64893A (en) 1993-07-16
IT8767594A0 (it) 1987-07-10
IE60290B1 (en) 1994-06-29
SG64393G (en) 1993-08-06
CH671157A5 (de) 1989-08-15
AU611856B2 (en) 1991-06-27
NL192917B (nl) 1998-01-05
CN87104963A (zh) 1988-02-24
PT85343B (pt) 1990-04-30
CN1033738C (zh) 1997-01-08
NL192917C (nl) 1998-05-07
NO171828C (no) 1993-05-12
DE3723781C2 (de) 1999-09-02
GB2193631A (en) 1988-02-17
GB8716904D0 (en) 1987-08-26
IE871933L (en) 1988-01-18
KR930004597B1 (ko) 1993-06-01
GB2193631B (en) 1990-11-21
DK368387D0 (da) 1987-07-15
AT402259B (de) 1997-03-25
NO872966L (no) 1988-01-19
DE3723781A1 (de) 1988-01-21
DK171308B1 (da) 1996-09-02
SE8702907D0 (sv) 1987-07-17
PT85343A (en) 1987-08-01
AU7566587A (en) 1988-01-21
NL8701640A (nl) 1988-02-16
CA1297007C (en) 1992-03-10
IL83220A0 (en) 1987-12-31
NO171828B (no) 1993-02-01
FR2601591B1 (fr) 1991-04-26
HU198627B (en) 1989-11-28
IT1218927B (it) 1990-04-24
HUT44941A (en) 1988-05-30

Similar Documents

Publication Publication Date Title
SE8702907D0 (sv) Stable pharmaceutical preparation containing granulocyte colony stimulating factor and process for producing the same
DK339289D0 (da) Farmaceutisk praeparat
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
DE3577851D1 (de) Inositoltriphosphat, verfahren zu seiner herstellung und dieses enthaltende zubereitung.
FI900412A0 (fi) Antiviral eller antibakteriell foerening och foerfarande foer anvaendning daerav.
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
FR2612187B1 (fr) Derives du thiazole actifs sur le systeme cholinergique, leur procede de preparation et compositions pharmaceutiques en contenant
FR2543550B1 (fr) Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique
PT76502B (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
BG96513A (bg) Заместени 4-фенил-4-пиперидинкарбоксамиди с локален обезболяващ и болкоуспокояващ ефект и метод за тяхното получаване
PT85279A (fr) Procede de preparation de derives du nitrofurane et de compositions pharmaceutiques les contenant
IL103101A (en) Topical composition for rejuvenating skin
DE69632396D1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
DE59001005D1 (de) Hilfsmittelfreie riboflavingranulate.
FR2456097A1 (fr) Nouveaux derives de la 5 h-furanone-2 et de la 3 h-dihydrofuranone-2, leur procede de preparation et leur application en therapeutique
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
FR2565586B1 (fr) Derives de la naphtoxazine, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
LU81210A1 (fr) Nouveaux derives de 1,3-benzodioxine,procede de preparation et compositions pharmaceutiques
FR2642757B1 (fr) Nouveaux derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant
FR2665443B1 (fr) Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
FR2642754B1 (fr) Nouveaux derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant
KR970032876A (ko) 간장질환 치료용 의약 조성물
FR2597340B1 (fr) Compositions pharmaceutiques contenant de la vinburnine et leur procede de preparation.
FR2548668B1 (fr) Derives d'hexahydro-indolo-naphtyridines, leur preparation et leur application en therapeutique